Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2007-07-24
2007-07-24
Li, Ruixiang (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C514S012200
Reexamination Certificate
active
10451822
ABSTRACT:
The present invention provides proteins having the Na+/glucose transporter activity, DNAs encoding the proteins, a method of screening for a compound enhancing or inhibiting the activity of the proteins, and compounds obtained by the screening method. The proteins having the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, 15 or 26 are useful as a diagnostic marker for a disease such as diabetes. The compounds enhancing or inhibiting the activity of the proteins, obtained the screening method using the proteins, can be used as a prophylactic and/or therapeutic agent for a disease such as diabetes and hyperlipidemia.
REFERENCES:
patent: 2005/0196754 (2005-09-01), Drmanac et al.
patent: WO 00/18918 (2000-04-01), None
Database EMBL: Nov. 24, 2000; XP002305383; Database accession No. AL 109659/ the N-terminal part of the encoded protein of accession No. Q9NPZ7 (TrEMBL) is 100% identical to SEQ ID. No. 1 in a 68 amino acids overlap.
David G. Wang, et al., “Large-Scale Identification, Mapping, and Genotyping of Single-Nucleotide Polymorphisms in the Human Genome”, Science, (1998), pp. 1077-1082, vol. 280.
Jason T. Lam, et al., “Missense Mutations in SGLT1 Cause Glucose-Galactose Malabsorption by Trafficking Defects”, Biochimica et Biophysia Acta, (1999), pp. 297-303, vol. 1453, No. 2.
Kenji Tsujihara, “Na+-Glucose Cotransporter (SGLT) Inhibitors as Antidiabetic Agents. 4. Synthesis and Pharmacological Properties of 4'-Dehydroxyphlorizin Derivatives Substituted on the B Ring”, Journal of Medicinal Chemistry, (1999), pp. 5311-5324, vol. 42, No. 26.
Tarpey, et al. “Amino acid sequence and the cellular location of the Na+-dependent D-glucose symporters (SGLT1) inthe ovine enterocyte and the parotid acinar cell” BIOCHEM J 312:293-300 (1995).
Ana M. Pajor, “Sequence of aputative transporter from rabbit kidney related to the Na+/glucose cotransporter gene family” Biochem. Biophys. Acta 1194(2): 349-351 (1994).
Turk, et al. Structure of the Human Na+/Glucose Cotransporter Gene SGLT1 J. Biol. Chem. 269(21): 15204-15209 (1994).
Yang, et al. “Expression characteristics and relevance of sodium glucose cotransporter-1 in mammalian renal tubulogenesis” Am. J. Physiol. Renal Physiol. 279(4): F765-777 (2000).
Oku, et al. “T-1095, an Inhibitor of Renal Na+-Glucose Cotransporters, May Provide a Novel Approach to Treating Diabetes” DIABETES 48: 1794-1800 (1999).
C.I. Cheeseman, “Upregulation of SGLT-1 Transport Activity in Rat Jejunum Induced by GLP-2 Infusion in vivo” Am. J. Physiol. 273: R1965-1971 (1997).
Nippon Rinsho (Japan Clinical), 55: 59-64 (1997), Extra Volume “Diabetes 1”.
Iwamoto Keiji
Katayama Nozomi
Kawamura Mihoko
Conlin David G.
Edwards Angell Palmer & & Dodge LLP
Hazzard Lisa Swiszcz
Li Ruixiang
Takeda Pharmaceutical Company Limited
LandOfFree
Proteins having glucose transporter activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Proteins having glucose transporter activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Proteins having glucose transporter activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3793531